What is behind the fear of cancer during menopausal hormone therapy in China?

• Published in: Archives of gynecology and obstetrics Vol. 304; no. 5; pp. 1353 - 1361
• Main Authors: Wang, Yanfang, Wang, Wei, Feng, Ying, Tan, Zhangyun, Yang, Xiaomin, Peng, Danhong, Zhao, Yinqing, Dong, Han, Zheng, Qingmei, Zeng, Xiaoqin, Zou, Ying, Sun, Aijun
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01-11-2021; Springer Nature B.V
• Subjects: Breast cancer; Cancer; Endocrine therapy; Endocrinology; Endometrial cancer; Estrogens; Gynecologic Endocrinology and Reproductive Medicine; Gynecology; Human Genetics; Medicine; Medicine & Public Health; Obstetrics/Perinatology/Midwifery; Questionnaires; Obstetrician and gynecologist; Menopausal hormone therapy; Knowledge; National survey; Cancer risk
• ISSN: 0932-0067; 1432-0711
• DOI: 10.1007/s00404-021-06052-4

Purpose
The application of menopausal hormone therapy (MHT) is generally restricted most likely due to limited prescriptions by doctors. Fear of cancer risk may be a critical factor. We investigated the views of Chinese obstetricians and gynecologists on the relationship between hormone therapy and cancer risk.
Methods
A self-administered web-based nationwide cross-sectional questionnaire.
Results
In total, 5243 medical workers responded to the questionnaire (response rate 94.5%); 4995 were certified obstetricians and gynecologists. Most were aged 36–55 years (70.9%), had > 10 years of working experience (68.5%), and worked at tertiary (34.8%) and secondary hospitals (49.1%); 70% of the clinicians were aware of the endometrial cancer risk caused by estrogen, and 20% considered progestogen to cause the same risk. Regarding breast cancer, while 67.9 and 74.8% of the clinicians viewed natural and synthetic estrogens as risk factors, respectively, only 41.7% identified the carcinogenic effect of progestins as higher than that of progesterone (26.7%). Approximately 75% of the participants believed synthetic estrogens and progestins constituted a risk for ovarian cancer (higher than the percentages for their natural counterparts); 13.0–21.1% of the respondents were worried about choriocarcinoma due to hormone treatment. Finally, 86.8% of obstetricians and gynecologists claimed to have poor knowledge regarding this field.
Conclusion
Misconceptions and a lack of knowledge in this regard may result in the fear of cancer and could be the underlying causes of limited MHT prescriptions. We believe that scientific research, continued education, and the media all have roles to play in changing preconceived ideas regarding MHT prescriptions.